BioAffinity Technologies Inc. (BIAF)
NASDAQ (CM) NASDAQ (CM) Primary Summary
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
bioAffinity Technologies Inc (NASDAQ: BIAF) shares are trading sharply higher Friday morning after the company reported full-year 2025 results highlighting strong growth in its flagship CyPath Lung diagnostic, even as total revenue declined following a strategic shift away from lower-margin lab services. Here's what investors need to know.
BioAffinity Technologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SAS Stephane Astruc/ Salomon Sebban J. Safra Sarasin Holding AG | 42,600 | $164,010 | $69,438 | -$94,572 | -57.66% |
| KMT Kirk M. Tokheim Ameritas Advisory Services LLC | 1,000 | $3,830 | $1,640 | -$2,190 | -57.18% |
BioAffinity Technologies Inc. (BIAF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioAffinity Technologies Inc. ever had a stock split?
BioAffinity Technologies Inc. Profile
| Professional Services Industry | Industrials Sector | Maria Zannes CEO | NASDAQ (CM) Exchange | 09076W307 CUSIP |
| US Country | 57 Employees | - Last Dividend | 19 Sep 2025 Last Split | - IPO Date |
Overview
bioAffinity Technologies, Inc. is an innovative company at the forefront of non-invasive diagnostic development for early-stage lung cancer and other lung diseases. Since its inception in 2014, the company has dedicated itself to advancing healthcare through the early detection of lung diseases, a vital step in improving patient outcomes. Based in San Antonio, Texas, bioAffinity Technologies is committed to offering groundbreaking solutions for the early diagnosis of life-threatening conditions, aiming to significantly impact public health positively.
Products and Services
- CyPath Lung
The flagship product of bioAffinity Technologies, CyPath Lung, represents a significant advancement in the field of lung disease diagnostics. This non-invasive diagnostic test is designed for the early detection of lung cancer, targeting one of the most common and deadliest forms of cancer worldwide. By focusing on early-stage detection, CyPath Lung aims to improve survival rates by enabling earlier and more effective treatment options for patients.
